Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

OnCusp Completes $100 Million Series A Round for In-Licensed Cancer Candidates

publication date: Jan 10, 2024

OnCusp Therapeutics, a New York City-Shanghai biopharma, completed an oversubscribed $100 million Series A financing round from China investors. The company plans to advance in-licensed cancer assets from pre-IND studies to proof of concept, considering this stretch to be the largest value inflection point in drug development. OnCusp will use the proceeds to advance CUSP06, an ADC targeting CDH6, toward clinical proof-of-concept. OnCusp acquired global rights (ex-China) to CDH6 from Multitude Therapeutics, a Shanghai-Redwood City ADC company. OnCusp’s A round was co-led by Novo Holdings, OrbiMed and F-Prime Capital. More details....

Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital